Top

Journal of Radiation Oncology

Published in:

01-12-2020 | Breast Cancer | Original Research

A comparison of quality of life and acute toxicity in patients applied with Tomo-helical IMRT and conformal radiotherapy for breast cancer

Authors: Eda Erdis, Birsen Yucel, Seher Bahar

Published in: Journal of Radiation Oncology | Issue 3-4/2020

Abstract

Aim

To compare quality of life and radiation toxicity in patients applied with Tomo-helical intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) as adjuvant radiotherapy because of breast cancer.

Material and method

The study included a total of 403 patients. Fifty-eight percent of patients were treated with 3D-CRT, and 42% of patients were treated with Tomo-helical IMRT. Radiation toxicity was evaluated according to the Radiation Therapy Oncology Group (RTOG) toxicity criteria. Quality of life was evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Quality of life scale version 3-Turkish and the EORTC QLQ-BR23 questionnaires. These questionnaires were completed by all patients at 4 different time points: the start of RT (T₁); the end of RT (T₂); 1 month after completion of RT (T₃); and 6 months after completion of RT (T₄). Statistical data were analysed using the Chi-square and MANOVA tests.

Results

Radiotherapy-related skin, upper gastro-intestinal system, white blood count and neutrophil toxicity were observed to be higher in the patients treated with 3D-CRT (p < 0.001). No difference was determined between the radiotherapy techniques according to the EORTC-C30 (p > 0.050). In the patients treated with Tomo-helical IMRT, the scores of breast symptoms (p = 0.014), sexual function (p = 0.003) and sexual pleasure (p = 0.020) in the sub-dimension scales of the EORTC-BR23 were found to be better compared with those of patients treated with 3D-CRT.

Conclusion

The findings of RT toxicity and quality of life appear to be superior in patients applied with Tomo-helical IMRT compared with patients treated with 3D-CRT.

Cuzick J, Stewart H, Peto R et al (1987) Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat 71:15–29

Early Breast Cancer Trialists’ Collaborative Group (2000) Favorable and unfavorable effects on long term survival of radiotherapy for early breast cancer. Lancet 355:1757–1770CrossRef

Kolitsi Z, Dahl O, Van Loon R et al (1997) Quality assurance in conformal radiotherapy: DYNARAD concensus report on practice guidelines. Radiother Oncol 45:217–223CrossRef

Vicini FA, Sharpe M, Kestin L et al (2002) Optimizing breast cancer treatment efficacy with intensity-modultated radiotherapy. Int J Radiat Oncol Biol Phys 54:1336–1344CrossRef

Lo YC, Yasuda G, Fitzgerald TJ et al (2000) Intensity modulation for breast teratment using static multileaf colimators. Int J Radiat Oncol Biol Phys 46:187–194CrossRef

Krueger EA, Fraass BA, Pierce LJ (2002) Clinical aspect of intensity-modultated radiotherapy in the treatment of breast cancer. Semin Radiat Oncol 12(3):250–259CrossRef

Hurksmans CW, Cho BC, Damen E et al (2002) Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol 62:163–171CrossRef

Andratschke N, Maurer J, Molls M, Trott K (2011) Late radiatioon-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanism and strategies of prevention. Radiother Oncol 100:160–166CrossRef

Offersen B, Hojris I, Overgaard M (2011) Radiation-induced heart morbidity after adjuvant radiotherapy of early breast cancer- is it still an issue? Radiother Oncol 100:157–159CrossRef

10.

O’Donnell H, Cookey K, Walshy N, Plowman PN (2009) Early experience of Tomotherapy-based intensity-modulated radiotherapy for breast Cancer treatment. Clin Oncol 21:294–301CrossRef

11.

Henry AA, Youlia AF, Kirova M (2017) Evolution of radiation techniques in the treatment of breast cancer (BC) patients: from 3D conformal radiotherapy (3D-CRT) to intensity-modulated RT (IMRT) using helical Tomotherapy (HT). Radiother Oncol 124:333–334CrossRef

12.

Van Gestel D, van Viliet-Vroegindeweig C, Van den Heuvel F, Crijns W, Coelmont A, De Ost B, Holt A, Lamers E, Geussens Y, Nuyts S, Van den Weyngaert D, Van den Wyngaert T, Vermorken JB, Gregoire V (2013) RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiat Oncol 8:1–11CrossRef

13.

Han EY, Paudel N, Sung J, Yoon M, Chung WK, Kim DW (2016) Estimation of the risk of secondary malignancy arising from whole-breast irradiation: comparison of five radiotherapy modalities. including TomoHDA Oncotarget 7(16):60–69

14.

Schubert LK, Gondi V, Sengbusch E et al (2011) Dosimetric comparison of left sided whole breast irradiation with 3DCRT, forward planned IMRT, inverse planned IMRT, helical tomotherapy and topotherapy. Radiother Oncol 100(2):241–246CrossRef

15.

Goddu SM, Chaudhari S, Mamalui-Hunter M et al (2009) Helical tomotherapy planning for left-sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique. Int J Radiat Oncol Biol Phys 73:1243–1251CrossRef

16.

Aaronson NK, Cull A, Kaasa S et al (1996) The European Organization of Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology: and update. In: Spilker B (ed) Quality of life and Pharmacoeconomics in clinical trials, 2nd edn. Raven Press, New York, NY, pp 179–189

17.

Gotay CC, Wilson M (1998) Use of quality-of-life outcome assessments in current cancer clinical trials. Evaluation of Health Prof 1998(21):157–178

18.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) For the European Organization for Research and Treatment of Cancer study group on quality of life. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst 85:365–376CrossRef

19.

Harsolia A, Kestin L, Grills I et al (2007) Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68:1375–1380CrossRef

20.

Freedman GM, Anderson PR, Li J et al (2006) Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol 29:66–70CrossRef

21.

Mc Donalds MW, Godette K, Butker E et al (2008) Long-term outcomes of IMRT for breast cancer: in single-institution cohort analysis. Radiat Oncol Biol Phys 72:1031–1040CrossRef

22.

Almberg SS, Lindmo T, Frengen J (2011) Superficial doses in breast cancer raditherapy using conventional and IMRT techniques: a film-based phantom study. Radiother Oncol 100:259–264CrossRef

23.

Budischewski K, Fischbeck S, st M (2008) Quality of life of breast cancer patients in the course of adjuvant radiotherapy. Support Care Cancer 16:299–304CrossRef

24.

Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310CrossRef

25.

Hoyer BB, Toft GV, Debess J et al (2011) A nurse-led telephone session and quality of life after radiotherapy among women with breast cancer: a randomized trial. Open Nurs J 5:31–37CrossRef

26.

Marta GN, Moraes FY, Leite ETT, Chow E, Cella D, Bottomley A (2017) A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. Ann Palliat Med 6(Suppl 2):223–232CrossRef

27.

Donovan E, Bleakley N, Denholm E et al (2007) Randomised trial of standard 2D radiotherapy versus intensity-modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82:254–264CrossRef

28.

Pignol JP, Olivotto I, Rakovitch E et al (2008) A multicenter randomized trial of breast intersity-modulated radiation therapy to reduced acute radiation dermatitis. J Clin Oncol 26(13):2085–2092CrossRef

29.

Versmessen H, Vinh-Hung V, Van Parijs H et al (2012) Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer 12:495CrossRef

Title: A comparison of quality of life and acute toxicity in patients applied with Tomo-helical IMRT and conformal radiotherapy for breast cancer
Authors: Eda Erdis
Birsen Yucel
Seher Bahar
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: Journal of Radiation Oncology / Issue 3-4/2020
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-020-00432-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Material and method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3-4/2020

SBRT re-irradiation after prior SBRT in pancreatic cancer—outcomes and a focus on stomach and bowel toxicity

Efficacy of palliative SBRT in local control of sarcoma

Lymph node–directed simultaneous integrated boost in patients with clinically lymph node–positive cervical cancer treated with definitive chemoradiotherapy: clinical outcomes and toxicity

Impact of lung tumor motion on dose delivered to organ at risk in lung stereotactic body radiation therapy

Volumetric modulated craniospinal irradiation workflow optimization through quantitative analytics: a single-institution case study comparing pediatric and adult settings

Keynote webinar | Spotlight on antibody–drug conjugates in cancer